[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"remote-ischaemic-preconditioning\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:remote-ischaemic-preconditioning":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100611204",false,"NCT07237542","Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction","Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction (RIC-END): A Randomised Multicentre Trial","RIC-END","Inclusion Criteria:\n\n1. Age 18 years or older;\n2. Diagnosed with acute ischemic stroke;\n3. Clinical symptoms consistent with perforating artery infarction (NIHSS score ≤5, with consciousness item 1a ≤1);\n4. Time from onset to randomization within 48 hours;\n5. Diffusion-weighted imaging (DWI) showing a single infarct in the perforating artery territory with a maximum diameter ≤30 mm, meeting at least one of the following:\n\n(1) Diameter ≤15 mm and involving two or more axial slices; (2) Maximum diameter ≥15 mm; (3) Connected to the ventral surface of the pons but not crossing the midline; 6) Stenosis of parent artery \\\u003C70%; 7) Signed informed consent obtained from the patient or their legally authorized representative.\n\nExclusion Criteria:\n\n1. Received intravenous thrombolysis or endovascular treatment prior to randomization;\n2. Secondary stroke caused by brain tumor, traumatic brain injury, hematologic disorders, or other conditions;\n3. History of intracranial hemorrhage;\n4. Presence of RIC contraindications, such as severe upper limb soft tissue injury, fracture, subclavian artery stenosis, or peripheral vascular disease;\n5. Uncontrolled severe hypertension (systolic blood pressure \\[BP\\] ≥180 mmHg or diastolic BP ≥110 mmHg);\n6. Severe hepatic or renal dysfunction (Alanine Aminotransferase or Aspartate Aminotransferase \\> 3 × upper limit of normal; creatine kinase \\>3 × upper limit of normal; estimated Glomerular Filtration Rate \\\u003C 30 mL \u002F min \u002F 1.73 m²);\n7. Patients with thrombocytopenic purpura, coagulation disorders, or active visceral bleeding;\n8. Patients in the acute phase of fundus hemorrhage;\n9. History of severe aphasia or psychiatric disorders affecting clinical assessment;\n10. Life expectancy \\\u003C90 days;\n11. Pregnancy;\n12. Inability to comply with follow-up;\n13. Participation in other clinical trials.","ALL","18 Years",{"count":19,"type":20},910,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to conduct a prospective, randomized, double-blind, multicenter, parallel-controlled, group-sequential trialto scientifically evaluate the safety and efficacy of remote ischemic preconditioning (RIC) in preventing early neurological deterioration (END) in patients with acute perforating artery infarction (PAI).",[26,27],"Ischemic Stroke","Remote Ischaemic Preconditioning",[29,30,31,32],"perforating artery stroke","remote ischemic preconditioning","early neurological deterioration","randomized controlled trial","RECRUITING","2026-01-30",{"date":36,"type":37},"2026-02-03","ACTUAL",{"date":39,"type":37},"2025-12-11",{"date":41,"type":20},"2027-11-20",{"name":43,"class":44},"Jinling Hospital, China","OTHER",""]